Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

October 6, 2017: By Joan McKenna
Alcon's AutonoMe

Alcon’s AutonoMe

Alcon’s AutonoMe preloaded intraocular lens delivery system for its Clareon IOL has gained CE mark approval, parent Novartis announced Oct. 6.

The new device will be introduced with the Clareon IOL at the 2017 meeting of the European Society of Cataract and Refractive Surgeons in Lisbon, Portugal.

“Throughout Alcon’s history, we have worked with doctors to enhance and transform the way cataract surgery is performed,” said Mike Ball, chief executive officer of Alcon, in Fort Worth Texas. “Clareon AutonoMe builds upon the comprehensive legacy of AcrySof by offering cataract surgeons easy, intuitive control of IOL delivery with the newest optic material.”

Features of the AutonoMe include an automated CO2-powered delivery mechanism and an intuitive, ergonomic design to allow precise and simplified single-handed control of IOL placement during cataract surgery, Switzerland-based Novartis said.

The Clareon hydrophobic acrylic IOL, made of a new biomaterial designed to provide sharp vision and optical clarity, received CE mark approval in May.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022